Recent News

• 09.10.2025 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
• 09.10.2025 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
• 09.10.2025 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
• 09.08.2025 - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
• 09.08.2025 - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
• 09.04.2025 - TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Recent Filings

• 08.08.2025 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers